Navigation Links
BioSpecifics Technologies Corp. to Present at CapStone Investments' Third Annual Small-Cap Investor Conference
Date:7/22/2009

LYNBROOK, N.Y., July 22 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming CapStone Investments' Third Annual Small-Cap Investor Conference on Wednesday, July 29, 2009, at 9:30am CT at the Hyatt Regency in Milwaukee, WI.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link:http://www.wsw.com/webcast/capstone/bstc.ob/.

An archived version of the webcast will be available for 90 days on the BioSpecifics website.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
2. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
3. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
4. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
5. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
6. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
7. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
8. BioSpecifics Technologies Corp. Buys Down Royalties for Peyronies Disease
9. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
10. BioSpecifics Technologies Corp. Announces Additional Sales of Stock in Private Placement Offering
11. BioSpecifics Technologies Corp. Announces Sale of Stock in Private Placement Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Denmark , March 22, 2017  Ascendis ... utilizes its innovative TransCon technology to address significant ... financial results for the full year ended December ... significant year for our company as we broadened ... a leading, integrated rare disease company with an ...
(Date:3/22/2017)...   iSpecimen ®, the marketplace for ... Service (DPS), a full-service anatomic pathology reference lab ... States , has joined a program offered by ... (DHIN) to make human biospecimens and associated data available ... announced in 2015 as a collaboration between iSpecimen and ...
(Date:3/22/2017)... CAMBRIDGE, Mass. , March 22, 2017   ... of next-generation cancer therapeutics designed to target cancer stemness ... Patricia S. Andrews as Chief Executive Officer, ... will succeed Chiang J. Li , M.D., FACP, ... company ten years ago. Under his leadership, Boston Biomedical ...
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation is ... the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, there ... therapeutic antibodies. , To meet this demand, the team at SCIEX has ...
Breaking Biology Technology:
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):